|
|
Combination Therapy With Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected With Human Immunodeficiency Virus Type 1
Starr, Stuart E.; Fletcher, Courtney V.; Spector, Stephen A.; et al.; New England Journal of Medicine (12/16/99) Vol. 341, No. 25, P. 1874.
A recent study involving HIV-1-infected children studied the use of antiretroviral therapy consisting of efavirenz, nelfinavir, and one or more nucleoside reverse-transcriptase inhibitors. The 57 young subjects, ages three to 16, were monitored for 48 weeks after therapy began. Before the study started, all but two of the children were receiving one or more nucleoside reverse-transcriptase inhibitors.
Two of the most common adverse effects of the treatment were rash, which was reported in 30 percent of the subjects, and diarrhea, which was reported in 18 percent. Only one child had a life-threatening adverse effect; the child developed neutropenia with concurrent varicella. Overall, the authors found that combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors was tolerated well by the children in the study.
The use of such a regimen, which produced "potent and sustained antiviral effects," is an important addition to the antiviral treatments available for HIV-infected children, the researchers concluded.
Go to the Combination Therapy Menu
Go to the Treatments for HIV/AIDS Menu
Go to the HIVpositive.us Main Menu